The impact of regulatory requirements and the Clinical Negligence Scheme for Trusts (CNST) on point of care testing (Poct) were among the topics discussed at two meetings hosted by Bayer Diagnostics
The meetings, held at Blenheim Palace, Oxfordshire and the Victoria and Albert Hotel, Manchester, also focused on the future role of pharmacists in the provision of Poct, stimulating lively discussion on this controversial topic.
Those attending the Blenheim Palace meeting heard additional presentations on the role of blood gas analysis in a study of altitude sickness and the value of microalbumin as a marker for assessing critically ill patients.
At the Manchester meeting, presentations also looked at new studies in Poct and the support for Poct during Manchester's Pharmacy Project.
Both meetings were structured to provide detailed insights into key issues currently affecting those with responsibility for Poct - an area of diagnostics which is expected to grow significantly in the next decade.
Delegates also had the opportunity to participate in breakout workshop sessions focusing on the practicalities of blood gas analysis, diabetes control and urinalysis, whilst also sharing experiences and opinions with their peers.
Feedback from delegates was extremely positive|: "A very useful and enjoyable meeting with much attention to detail", "A welcome debate on the pharmacy role", "I found the overall experience of great value" - were just some of the comments received.
Bayer's new and improved Clinitek 500 urine chemistry analyser was on show at both meetings, giving delegates the chance to see the system in action and appreciate the simplicity of its enhanced touch screen user interface.
